![Page 1: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/1.jpg)
Update in Endoscopic Therapy for Upper GI Malignancies
Jon P Walker, MD MSThe Ohio State University Medical Center
October 8th, 2010
![Page 2: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/2.jpg)
Disclosure
• No financial disclosures to report• Will discuss off-label usage of a product.
![Page 3: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/3.jpg)
Overview
• Endoscopic management of high grade dysplasia
• Endoscopic management of superficial malignancies
• Maintenance of Luminal Patency
![Page 4: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/4.jpg)
Management of High Grade Dysplasia and Superficial Malignancy
• Surgical management (resection)– First consideration– Surgical candidate?
• Radiofrequency ablation– BARRX
• Photodynamic therapy• Endoscopic mucosal resection
– Nodule– Clearing of focal area of dysplasia
![Page 5: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/5.jpg)
Management of High Grade Dysplasia and Superficial Malignancy
• Endoscopic therapy for superficial malignancy only!– No seriously…really superficial malignancy.– T1sm vs T1m very important– Mucosal involvement 5-8% LN involvement– Submucosal involvement 25-40% LN involvement
![Page 6: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/6.jpg)
Endoscopic Mucosal Resection• Procedure
– Submucosal injection of saline/epinephrine/dye– Banding of the lesion; snare resection of the lesion
• Benefit: Both staging & resection– Planning of next step in treatment– Inaccuracy of EUS staging
• EUS 29% accurate for T1 tumors & 45% accurate for T2 tumors. (Zuccaro et al Am J Gastroenterol 2005)
• Recent studies showing accuracy 70-80%
• Risks– Bleeding, perforation, chest pain, stricture
• Follow up ablative therapy
![Page 7: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/7.jpg)
Endoscopic Mucosal Resection
![Page 8: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/8.jpg)
Endoscopic Mucosal Resection
Courtesy Todd Baron MD; Dave Project.org
![Page 9: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/9.jpg)
Endoscopic Mucosal Resection
• 68y/o WM with recent EGD for epigastric pain.• EGD: Approx 1cm sessile lesion in setting of
short segment Barretts esophagus• Biopsy: high grade dysplasia with at least
intramucosal adenocarcinoma• Multiple medical problems. Considered poor
candidate for elective esophagectomy• EUS: T1m lesion; No lymphadenopathy
![Page 10: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/10.jpg)
Endoscopic Mucosal Resection
![Page 11: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/11.jpg)
Endoscopic Mucosal Resection
![Page 12: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/12.jpg)
Endoscopic Mucosal Recection
• Follow up pathology: HGD w/ intramucosal carcinoma.
• No evidence of lymphovascular invasion• No evidence of submucosal invasion• Scheduled for subsequent Barrett’s ablation
![Page 13: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/13.jpg)
Endoscopic Mucosal Resection
• 75y/o WM with recent EGD for anemia• Demonstrated 1.5cm distal esophageal lesion• Biopsy revealed high grade dysplasia w/ at
least intramucosal carcinoma• Poor surgical candidate for elective
esophagectomy• EUS: T1m lesion. No lymphadenopathy• EMR performed
![Page 14: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/14.jpg)
Endoscopic Mucosal Resection
![Page 15: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/15.jpg)
Endoscopic Mucosal Resection
![Page 16: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/16.jpg)
Endoscopic Mucosal Resection
• Pathology: Well-differentiated adenocarcinoma with foci of submucosal invasion.
• Surgical options offered.
![Page 17: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/17.jpg)
Endoscopic Mucosal Resection
Low Risk Group• N=35• Limited to mucosa• Less than 2cm lesion• 97% achieved CR @12mos
High Risk Group• N=29• Some invasion of
submucosa• Greater than 2cm lesion• Poorly differentiated• 59% achieved CR @12mos
64 patients w/ HGD (n=3) or T1 EC (n=61) treated with EMR
Ell et al Gastroenterology 2000
vs
![Page 18: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/18.jpg)
Endoscopic Mucosal Resection
Low Risk Group• N=35• Limited to mucosa• Less than 2cm lesion• 97% achieved CR @12mos
High Risk Group• N=29• Some invasion of
submucosa• Greater than 2cm lesion• Poorly differentiated• 59% achieved CR @12mos
64 patients w/ HGD (n=3) or T1 EC (n=61) treated with EMR
Ell et al Gastroenterology 2000
vs
![Page 19: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/19.jpg)
Endoscopic Mucosal Resection• Follow up to prior study• 100 patients• Low risk • 37 months follow up• 99% local remission at 12 months• 11% metachronous lesion• Approx 50% ablative therapy of non-dysplastic
Barretts
Ell et al Gastrointest Endoscop 2007
![Page 20: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/20.jpg)
Ablative Therapies
• Laser• Argon Plasma Coagulation• Bipolar Electric Coagulation• Cryotherapy• Photodynamic Therapy• Radiofrequency Ablation
![Page 21: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/21.jpg)
Ablative Therapies
• Laser• Argon Plasma Coagulation• Bipolar Electric Coagulation• Cryotherapy• Photodynamic Therapy• Radiofrequency Ablation
![Page 22: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/22.jpg)
Photodynamic Therapy• Nonthermal ablative therapy• Administration of photosensitizing agent followed by
focal exposure of lesion to specific wavelength of light• Overholt et al Gastrointest Endoscopy 2003
– 105pts w/ HGD or Superficial Cancer– 78% eradication w/ HGD; 44% w/ cancer
• Overholt et al Gastrointest Endoscopy 2005– Similar findings w/ HGD
• Recurrence rate of up to 20%
![Page 23: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/23.jpg)
Photodynamic TherapyLimitations
• Chest pain• Odynophagia• Cutaneous Photosensitivity• Stricture
– 27-40% stricture formation reported– Risk factors for stricture
• Prior EMR• Prior stricture• Number of applications• Usually treatable with dilations
![Page 24: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/24.jpg)
Radiofrequency Ablation
• Topical focal application of radiofrequency ablation.
• Superficial uniform thermal therapy over wide-field
• Application by 360 or 90 degree delivery system
• Most frequent complication:chest pain
• Stricture rate: 0-8%
![Page 25: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/25.jpg)
Radiofrequency AblationShaheen et alNEJM 2009• Evaluation of BARRX
therapy for eradication of Barretts dysplasia
• 127 patients randomized to RFA vs sham
• 81% vs 19% total eradication of HGD
• 1.2% vs 9.3% development of cancer
• 6% stricture
Ganz et alGastointest Endosc 2006• 22 patients w/ RFA for HGD• 73% complete eradication• No stricture or serious
adverse effects
![Page 26: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/26.jpg)
Factors to Consider When Offering Endoscopic Therapy
• HGD only• Early Cancer within the mucosa only• Visible lesion less than 20mm• Well-differentiated to moderate• No lymph node involvement• No mets on CT• Patient desire to avoid surgery and compliance
with endoscopic follow-up
Sarah Rodriguez Esophageal Cancer 2009
![Page 27: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/27.jpg)
Luminal Access
• Stent placement– Polyflex stent placement– Metal stents
• Uncovered stent placement• Partially covered stent placement• Fully covered stents
• Photodynamic therapy• Laser therapy – Argon Beam Coagulation• Brachytherapy
![Page 28: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/28.jpg)
Stent Placement
![Page 29: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/29.jpg)
Stent Placement
![Page 30: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/30.jpg)
Stent Placement
• Issues to keep in mind– Chest pain– Migration– Palliation
• Will stent really improve current diet
– Tolerance for endoscopy– Reflux
![Page 31: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/31.jpg)
Plastic Stent Placement
• Polyflex stent - silicone• Removability• Temporary• Easy placement• Bridge to surgery• Difficult to assemble• Bulky (poorly tolerated)• Migration
![Page 32: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/32.jpg)
Polyflex Stent PlacementAdler et alGastrointestinal Endoscopy 2009
• 13 patient w/ Polyflex stent for neoadjuvant therapy
• No bleeding/perforation• Chest pain 12/13 patients• Dysphagia score from 3 to
1.1, 0.8,0.9,1.0 on weeks 1,2,3,4, respectively.
• Migration 6/13 patients at some point
Bowers et alAnnals of Surgical Oncology 2009
• 58 patients received stent, feeding tube or nothing
• Statistically better outcome in the stent group– Rate of interruption of chemo– Albumin level– Weight loss
• Migration rate: 24%
![Page 33: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/33.jpg)
Esophageal StentPolyflex
![Page 34: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/34.jpg)
Metal Stent Placement – Partially Covered
• Primarily esophageal• Permanent placement
– Epithelialization– Complication:better get them out early
• Primarily palliation– Luminal access– Fistula
• Decreased tumor ingrowth– Overgrowth or Undergrowth– Re-stent if needed
![Page 35: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/35.jpg)
Metal Stent – Fully Covered
• New product• Minimal migration• Minimal epithelialization• Permanent• ?Removable• Easy to place• Bridging therapy
– Radiaton is the issue– Removability is the issue
![Page 36: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/36.jpg)
Stent Placement
![Page 37: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/37.jpg)
Esophageal Stent Full-covered
![Page 38: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/38.jpg)
Esophageal StentsOther roles in esophageal malignancy
• Sticture patency maintenance– Post-radiation– Post-ablative therapy of high grade dysplasia– Post-operative anastomotic stricture
• Post-operative anastomotic leaks– Requires removable/temporary stent
• Fistulas– Tracheoesophageal fistula– Secondary to tumor or radiation therapy
• Determination of stent type– Condition duration– Patient prognosis– Luminal diameter– Location of defect
![Page 39: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/39.jpg)
Metal Stent - Uncovered
• Primarily palliation• Distal stomach and
small bowel• Must consider biliary
access prior to placement
• Tumor ingrowth factor
![Page 40: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/40.jpg)
Duodenal Stent
![Page 41: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/41.jpg)
Distal Gastric/Proximal Duodenal Tumors
• Gastric outlet obstruction• Options
– Surgical Gastrojejunostomy (GJJ)– Endoscopic intraluminal stent placement
• Dutch SUSTENT Study Group– Long term multicenter trial comparing palliative measures for GOO
secondary to malignant obstruction• Stent placement for palliation better than GJJ in patients with
life expectancy less than 2 months• GJJ better if longer survival anticipated
– Jeurnink Gastrointestinal Endoscopy, 2010– Jeurnink Journal of Gastroenterology, 2010
![Page 42: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/42.jpg)
Metal Wall Stent – UncoveredDistal Small Bowel
![Page 43: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/43.jpg)
Distal Small Bowel Obstruction
![Page 44: Update in Endoscopic Therapy for Upper GI Malignancies](https://reader033.vdocuments.us/reader033/viewer/2022042710/58eecf071a28abdc1c8b459d/html5/thumbnails/44.jpg)
Time is shortening. But every day that I challenge this cancer and survive is a victory for me.Ingrid Bergman